Diligence memo · auto-generated · as of July 2, 2026
Debut Biotechnology, Inc.
Debut Biotechnology, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Debut Biotechnology, Inc. operates in Biotech, based in SAN DIEGO.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Debut Biotechnology, Inc. has raised $31M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $23M on 2021-07-30.
Most recent recorded round closed around 2021-11-08.
Valuation (modeled)modeled
Provath models Debut Biotechnology, Inc. at approximately $89M (range $8.0M–$264M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.48× the median modeled value of Series B Biotech companies in 2019–2021 (5 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 4.6 yr ago; this sector typically re-raises about every 11 months.
Silent for over 3× the sector's normal cadence.
The last round was 5.7× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 94% of Biotech peers (233 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: 54Gene, Inc., hC Bioscience, Inc., Trace Genomics, Inc., CRISPR Therapeutics AG.
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.